结核分枝杆菌复合群在感染期间的宿主内突变适应
该meta分析汇总1044例结核患者的5882株高质量基因组,用趋同进化方法识别宿主内高频突变位点。研究发现21个基因、25个操纵子和27个启动子区域显著富集突变,涉及耐药与致病相关位点,其中氟喹诺酮类耐药在治疗期间获得频率高于其他抗结核药物。
要点
- 宿主内高频突变基因主要与耐药相关,也涉及ESX-1等致病通路。
- 氟喹诺酮类耐药在治疗期间获得频率高于其他抗结核药物。
- 鉴定出21个基因、25个操纵子和27个启动子区域显著富集突变。
核心结论
- MTBC宿主内高频突变基因揭示已知和新发现的适应,主要与耐药相关,也与致病相关。
- 氟喹诺酮类在治疗期间耐药获得率高于其他抗结核药物,可能具重要临床意义。
研究设计与样本
- 对同一患者多分离株测序的MTBC菌株进行meta分析,数据来自已发表研究和TB Portals。
- 纳入1044例结核患者的5882株高质量基因组,采用趋同进化方法识别跨患者高频突变位点。
主要发现
- 鉴定出21个基因、25个操纵子和27个启动子区域突变显著富集。
- 高频突变位点包括涉及一线、二线和末线抗结核药物耐药的多个位点。
- 既往报道的候选耐药/耐受基因prpR、Rv2571c、fadD11、helY、ndhA、Rv0139、fadE5、bioF2和mce1操纵子也被识别。
- 毒力ESX-1位点的调控基因phoR、whiB6、mycP1及效应基因espK、eccE1在宿主内频繁突变。
- 氟喹诺酮类耐药在治疗期间获得频率高于其他任何抗结核药物。
临床怎么用
- 治疗期间需关注氟喹诺酮类耐药获得风险,可能影响药物选择。
- 宿主内高频突变位点可辅助识别耐药与致病相关适应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis (TB) is the leading cause of death from an infectious disease worldwide. Mutations arising in Mycobacterium tuberculosis complex (MTBC) strains during TB infection provide a record of bacterial adaptations, such as those needed to survive the attack of the immune system and antibiotic therapies. METHODS: We conducted a meta-analysis of MTBC sequenced strains with multiple isolates from the same patient, sourced from published studies and TB Portals. We applied a convergent evolution approach to identify heavily mutated MTBC loci across patients and estimated the rates of drug resistance (DR) acquisition during treatment. RESULTS: Using 5882 high-quality genomes from 1044 patients with TB, we identified 21 genes, 25 operons, and 27 promoter regions statistically enriched by mutations compared with the rest of the genome, and additional loci with established and plausible adaptive roles approaching statistical significance. Significantly, these included multiple loci known to be involved in resistance to first-, second-, and last-line anti-TB drugs. Previously reported candidate drug-resistance and -tolerance genes (prpR, Rv2571c, fadD11, helY, ndhA, Rv0139, fadE5, bioF2, and mce1 operon) were also identified. Genes encoding regulators (phoR, whiB6, and mycP1) and effectors (espK and eccE1) of the virulence ESX-1 locus were frequently mutated in host. Fluoroquinolone resistance was acquired more frequently during treatment than resistance to any other anti-TB drug. CONCLUSIONS: We show that frequently mutated genes in MTBC reveal expected and newly discovered in host adaptations, predominantly associated with DR but also with pathogenesis. The higher resistance acquisition rate observed for fluoroquinolones may have important clinical relevance.
引用
- Zhang H, Medina-Jaudes N, Forcada-Nadal A, et al. In Host Mutational Adaptation of Mycobacterium Tuberculosis Complex Strains During Tuberculosis Infection. J Infect Dis. 2026. PMID: 42047497. doi:10.1093/infdis/jiag209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。